UY25923A1 - Composición farmacéutica para el tratamiento de diabetes mellitus.- - Google Patents
Composición farmacéutica para el tratamiento de diabetes mellitus.-Info
- Publication number
- UY25923A1 UY25923A1 UY25923A UY25923A UY25923A1 UY 25923 A1 UY25923 A1 UY 25923A1 UY 25923 A UY25923 A UY 25923A UY 25923 A UY25923 A UY 25923A UY 25923 A1 UY25923 A1 UY 25923A1
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical composition
- treatment
- diabetes mellitus
- administration
- methyl
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- -1 2-piperidino-phenyl Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 150000007529 inorganic bases Chemical class 0.000 abstract 1
- 238000012153 long-term therapy Methods 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Una composición farmacéutica para el tratamiento de diabetes mellitus en terapia de largo plazo mediante la cual, al utilizar la dosis simple en lugar de la doble en la administración de la sal o éter del ácido racémico correspondiente, se evita la innecesaria carga alta y de larga duración de sustancias, como resultado de lo cual se obtienen niveles sustancialmente inferiores de sustancia activa en el plasma que van mucho más allá de la ventaja normal de reducir a la mitad la dosis en la administración de enantiómeros que contienen una cantidad eficaz de ácido benzoico de -(S) (+)-2-etoxi-4-[N-[1-(2-piperidino-fenil)-3-metil-1-butil]aminocarbonil-metil] o una sal fisiológicamente aceptable del mismo con ácidos o bases orgánicos o inorgánicos conjuntamente con uno o más vehículos y/o diluyentes inertes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002111851A CA2111851C (en) | 1991-06-21 | 1991-06-21 | (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid |
PCT/EP1991/001147 WO1993000337A1 (de) | 1991-06-21 | 1991-06-21 | (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure |
SG1996002715A SG43036A1 (en) | 1991-06-21 | 1991-06-21 | (S) (+) -2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl- 1-buthyl]aminocarbony methyl] - benzoic a cid |
CN91104984A CN1048722C (zh) | 1991-06-21 | 1991-07-22 | (s)(+)-2-乙氧基-4-[n-[1-(2-哌啶子基-苯基)-3-甲基-1-丁基]氨基羰基甲基]苯甲酸,含该化合物的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25923A1 true UY25923A1 (es) | 2001-08-27 |
Family
ID=36781542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25923A UY25923A1 (es) | 1991-06-21 | 2000-01-17 | Composición farmacéutica para el tratamiento de diabetes mellitus.- |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0589874B1 (es) |
JP (1) | JP2921982B2 (es) |
KR (1) | KR100496720B1 (es) |
CN (1) | CN1048722C (es) |
AU (1) | AU660930B2 (es) |
BG (1) | BG61690B1 (es) |
CA (1) | CA2111851C (es) |
DE (2) | DE10075006I2 (es) |
DK (2) | DK0589874T3 (es) |
FI (1) | FI106027B (es) |
GR (1) | GR3031654T3 (es) |
HK (1) | HK1011968A1 (es) |
NO (2) | NO303687B1 (es) |
PL (1) | PL170210B1 (es) |
RO (1) | RO113462B1 (es) |
SG (1) | SG43036A1 (es) |
SK (1) | SK281246B6 (es) |
UY (1) | UY25923A1 (es) |
WO (1) | WO1993000337A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1011673T3 (da) | 1997-06-13 | 2001-07-09 | Novo Nordisk As | Hidtil ukendt metode til behandling af nidom |
IN192862B (es) | 1999-11-16 | 2004-05-22 | Ranbaxy Lab Ltd | |
PE20020617A1 (es) | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
US20040102477A1 (en) * | 2002-08-23 | 2004-05-27 | Dr. Reddy's Laboratories Limited | Polymorphic forms of (S)-Repaglinide and the processes for preparation thereof |
US7915421B2 (en) * | 2003-05-14 | 2011-03-29 | Cilag Ltd. | Method for preparing phenyl acetic acid derivatives |
WO2004103983A1 (en) * | 2003-05-26 | 2004-12-02 | Biocon Limited | Process for the preparation of s(+)-2-ethoxy-4-[n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl]benzoic acid derivatives |
EP1664008A1 (en) * | 2003-08-28 | 2006-06-07 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous form of repaglinide |
CN1305863C (zh) * | 2004-12-27 | 2007-03-21 | 浙江大学 | (s)-异丙基-(2-哌啶)苯基-甲基胺的合成方法 |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
FR2898894B1 (fr) * | 2006-03-24 | 2008-06-06 | Genfit Sa | Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations |
US7763607B2 (en) * | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
WO2008051902A2 (en) * | 2006-10-20 | 2008-05-02 | Cpd, Llc | Method of restoring the incretin effect |
US8101769B2 (en) | 2007-02-15 | 2012-01-24 | Actavis Group Ptc Ehf | Process for preparing ethyl (S)-2-ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonyl methyl]benzoate and use thereof for the preparation of Repaglinide |
WO2009004485A2 (en) * | 2007-06-06 | 2009-01-08 | Actavis Group Ptc Ehf | Repaglinide substantially free of dimer impurity |
EP2019097A1 (en) | 2007-07-25 | 2009-01-28 | Aurobindo Pharma Limited | Process for preparing (alphaS)-alpha-(2-methylpropyl)-2-(1-piperidinyl)benzenemethanamine |
WO2009040818A1 (en) | 2007-09-25 | 2009-04-02 | Solubest Ltd | Compositions comprising lipophilic active compounds and method for their preparation |
DE102008046995B4 (de) * | 2008-09-12 | 2010-08-26 | Stada Arzneimittel Ag | 2-Ethoxy-benzoesäurederivat |
EP2177221A1 (en) | 2008-10-20 | 2010-04-21 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of substantially optically pure Repaglinide and precursors thereof |
PE20120403A1 (es) | 2009-05-15 | 2012-05-03 | Novartis Ag | Aril-piridinas como inhibidoras de sintasa de aldosterona |
CA2761853A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Benzoxazolone derivatives as aldosterone synthase inhibitors |
AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
EA201101672A1 (ru) | 2009-05-28 | 2012-06-29 | Новартис Аг | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина |
CN102712589B (zh) | 2009-11-17 | 2015-05-13 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基-吡啶衍生物 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
JP5575913B2 (ja) | 2009-11-30 | 2014-08-20 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
EP2364977A1 (en) | 2010-01-26 | 2011-09-14 | Reuter Chemische Apparatebau KG | Process for the enantiomeric enrichment of 3-methyl-1-(2-piperidinophenyl)-1-butylamine |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
CN102267959B (zh) * | 2011-07-06 | 2013-05-01 | 海南锦瑞制药股份有限公司 | 一种瑞格列奈晶体、其制备方法及含有该晶体的固体口服制剂 |
CN103012319B (zh) * | 2011-09-20 | 2015-06-10 | 浙江九洲药业股份有限公司 | 瑞格列奈中间体的合成工艺改进 |
CN102584743A (zh) * | 2011-12-28 | 2012-07-18 | 中国药科大学 | 对二甲氨基吡啶瑞格列奈共晶 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
PE20151666A1 (es) | 2013-02-14 | 2015-11-19 | Novartis Ag | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep |
CN105612172A (zh) | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | 用于治疗心力衰竭的环状多肽 |
PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
EP3215154B1 (en) | 2014-11-07 | 2020-01-29 | Regents of the University of Minnesota | Salts and compositions useful for treating disease |
BR112017014194A2 (pt) | 2015-01-23 | 2018-01-09 | Novartis Ag | conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada |
WO2018034627A1 (en) | 2016-08-18 | 2018-02-22 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Pharmaceutical composition of antidiabetic tablet |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3347565A1 (de) * | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
-
1991
- 1991-06-21 PL PL91301997A patent/PL170210B1/pl unknown
- 1991-06-21 SK SK1280-93A patent/SK281246B6/sk not_active IP Right Cessation
- 1991-06-21 DE DE2000175006 patent/DE10075006I2/de active Active
- 1991-06-21 WO PCT/EP1991/001147 patent/WO1993000337A1/de active IP Right Grant
- 1991-06-21 CA CA002111851A patent/CA2111851C/en not_active Expired - Lifetime
- 1991-06-21 SG SG1996002715A patent/SG43036A1/en unknown
- 1991-06-21 JP JP3511056A patent/JP2921982B2/ja not_active Expired - Lifetime
- 1991-06-21 DK DK91911959T patent/DK0589874T3/da active
- 1991-06-21 RO RO93-01692A patent/RO113462B1/ro unknown
- 1991-06-21 DK DK99101810T patent/DK0965591T3/da active
- 1991-06-21 DE DE59109151T patent/DE59109151D1/de not_active Expired - Lifetime
- 1991-06-21 AU AU80781/91A patent/AU660930B2/en not_active Expired
- 1991-06-21 KR KR1019930703974A patent/KR100496720B1/ko active
- 1991-06-21 EP EP91911959A patent/EP0589874B1/de not_active Expired - Lifetime
- 1991-07-22 CN CN91104984A patent/CN1048722C/zh not_active Expired - Lifetime
-
1993
- 1993-12-14 BG BG98300A patent/BG61690B1/bg unknown
- 1993-12-20 FI FI935724A patent/FI106027B/fi not_active IP Right Cessation
- 1993-12-20 NO NO934726A patent/NO303687B1/no not_active IP Right Cessation
-
1998
- 1998-12-08 HK HK98112967A patent/HK1011968A1/xx not_active IP Right Cessation
-
1999
- 1999-07-20 NO NO1999017C patent/NO1999017I1/no unknown
- 1999-10-27 GR GR990402743T patent/GR3031654T3/el unknown
-
2000
- 2000-01-17 UY UY25923A patent/UY25923A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO934726D0 (no) | 1993-12-20 |
SG43036A1 (en) | 1997-10-17 |
NO303687B1 (no) | 1998-08-17 |
PL170210B1 (pl) | 1996-11-29 |
FI935724A (fi) | 1993-12-20 |
HK1011968A1 (en) | 1999-07-23 |
KR100496720B1 (ko) | 2006-01-27 |
DE10075006I2 (de) | 2004-01-08 |
EP0589874B1 (de) | 1999-09-08 |
BG98300A (bg) | 1994-09-30 |
RO113462B1 (ro) | 1998-07-30 |
CN1068820A (zh) | 1993-02-10 |
BG61690B1 (bg) | 1998-03-31 |
FI935724A0 (fi) | 1993-12-20 |
JPH06508816A (ja) | 1994-10-06 |
NO934726L (no) | 1993-12-20 |
DK0965591T3 (da) | 2002-11-18 |
FI106027B (fi) | 2000-11-15 |
DE59109151D1 (de) | 1999-10-14 |
CA2111851C (en) | 2002-02-26 |
JP2921982B2 (ja) | 1999-07-19 |
NO1999017I1 (no) | 1999-07-20 |
WO1993000337A1 (de) | 1993-01-07 |
SK281246B6 (sk) | 2001-01-18 |
DE10075006I1 (de) | 2000-04-20 |
CN1048722C (zh) | 2000-01-26 |
EP0589874A1 (de) | 1994-04-06 |
DK0589874T3 (da) | 2000-04-03 |
CA2111851A1 (en) | 1993-01-07 |
SK128093A3 (en) | 1994-11-09 |
GR3031654T3 (en) | 2000-02-29 |
AU8078191A (en) | 1993-01-25 |
AU660930B2 (en) | 1995-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25923A1 (es) | Composición farmacéutica para el tratamiento de diabetes mellitus.- | |
Hernández et al. | Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19 | |
Exner et al. | Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial | |
Demello et al. | Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen | |
CY1114945T1 (el) | Φορεας φαρμακου και κιτ φορεα φαρμακου για την αναστολη ινωσης | |
UY26425A1 (es) | Formulación y método antidiabético | |
EE03292B1 (et) | Prootonpumba inhibiitorit sisaldav paljuosaline ravimpreparaat ja selle valmistamise protsess | |
Donovan et al. | Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide | |
AR004179A1 (es) | Sales de (endo,sin)-(-)-3-(3-hidroxi-1-oxo-2-fenilpropoxi)-8-metil-8-(1- metiletil)-8-azoniabiciclo[3.2.1] octano y preparaciones medicamentosasinhalativas que las contienen. | |
ES2093735T3 (es) | Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica. | |
SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
DK0490772T3 (da) | 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem | |
Bertini et al. | Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias | |
AR123570A1 (es) | Tratamientos para el edema macular diabético y la agudeza visual disminuida | |
CO2024002748A2 (es) | Profármaco de derivados de pirrolidona como activador de glucocinasa | |
US3230143A (en) | Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine | |
KR890004690A (ko) | 당뇨병의 치료를 위한 베자피브레이드의 용도 | |
NO912414L (no) | Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling. | |
ES2036560T3 (es) | Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. | |
Roberts et al. | Haemodynamic interactions of high-dose propranolol pretreatment and anaesthesia in the dog III: The effects of haemorrhage during halothane and trichloroethylene anaesthesia | |
EP2184066A1 (en) | Injection, injection solution and injection kit preparation | |
Arumugam et al. | A lethal injection? | |
ATE247462T1 (de) | Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist | |
Harder et al. | Effects of propafenone on TEA-induced action potentials in vascular smooth muscle of canine coronary arteries | |
ATE2746T1 (de) | Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20110408 |